Behandlung der idiopathischen männlichen Infertilität mit rekombinantem FSH: Ergebnisse einer kontrollierten Studie

Abstract

Objective: We prospectively studied the effect of recombinant follicle-stimulating hormone (FSH) in men with normogonadotropic oligoasthenoteratospermia. Methods: A total of 44 men with idiopathic oligoasthenoteratospermia (sperm concentration < 20 ×10 6 /mL, progressive motility < 50%, normal forms < 30%) received 75 IU of recombinant FSH daily for 6 weeks. Semen analysis was performed 2 weeks after the completion of treatment. The treated men were compared with 44 men with idiopathic oligoasthenoteratospermia who were observed without treatment for 6-8 weeks after initial diagnosis. The mean duration of infertility was 57 months (range, 12-193) in the treatment group and 61 months (range, 29-118) in the control group. At baseline there were no significant differences between the two groups in mean sperm concentration (5.5 × 10 6 vs. 5.1 × 10 6 /mL, respectively), progressive motility (20% vs. 31%, respectively), or normal morphology (8.9% vs. 15%). Results: Sperm concentration increased both in the treatment and in the control group (9.1 ×10 6 and 10.7 × 10 6 /mL). The other parameters were unchanged. Conclusion; Treatment of normogonadotropic oligoasthenoteratospermia with FSH at a dose of 75 IU/day for 6 weeks did not influence semen parameters.